01 June 2010
Trismus in head and neck cancer patients in Sweden: Incidence and risk factors
Joakim JohnsonBCDEF, Corina J. van As-BrooksCDEF, Bodil Fagerberg-MohlinABDE, Caterina FiniziaABCDEFGMed Sci Monit 2010; 16(6): CR278-282 :: ID: 880610
Abstract
Background: The aim was to retrospectively investigate trismus (reduced mandible mobility) development in specified head and neck (HandN) cancer diagnosis according to different radiotherapy dosage regimens.
Material/Methods: Sixty-nine out of 246 patients with different HandN cancer diagnoses and available maximum interincisal opening (MIO) measurements before and after treatment were analyzed according to age, gender, radiation dose, tumor site and stage, and Karnofsky Performance Status Scale index. MIO was measured over time (range: 3–48 months), with a cutoff criterion for trismus of 35 mm.
Results: Overall, 42% of the patients had post-treatment MIO <35 mm, and trismus incidence was highest in patients treated for parotid gland tumors followed by those treated for nasopharyngeal cancers. The mean MIO values at baseline were significantly different (p=0.0078) between patients who developed trismus (i.e. MIO <35 mm; mean: 43 mm) and those who did not (mean: 51 mm). The trismus patients also had significantly larger tumors (p=0.0437), poorer physical function before start of treatment (p=0.0344), and had more often received a higher total tumor radiation dose (p=0.0418).
Conclusions: This study reports a high incidence of trismus in HandN cancer patients after treatment. Furthermore, it was found that poor physical function before the start of treatment and high external beam radiation therapy (EBRT) dosages (>50 Gy) were related to significantly more trismus. Future prospective studies are needed to provide a better understanding of different risk factors associated with trismus development, the impact on health-related quality of life, and the effects of early treatment.
Keywords: Radiotherapy Dosage, Radiation Oncology - methods, Radiation Injuries, Incidence, Head and Neck Neoplasms - pathology, Aged, 80 and over, Risk Factors, Sweden, Trismus - etiology
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Clinical Research
Impact of Periodontal Treatment on Early Rheumatoid Arthritis and the Role of Porphyromonas gingivalis Anti...Med Sci Monit In Press; DOI: 10.12659/MSM.947146
Clinical Research
C-Reactive Protein, Uric Acid, and Coronary Artery Ectasia in Patients with Coronary Artery DiseaseMed Sci Monit In Press; DOI: 10.12659/MSM.947158
Clinical Research
Effects of Remote Exercise on Physical Function in Pre-Frail Older Adults: A Randomized Controlled TrialMed Sci Monit In Press; DOI: 10.12659/MSM.947105
Database Analysis
Development and Validation of a Competitive Risk Model in Elderly Patients with Transitional Cell Bladder C...Med Sci Monit In Press; DOI: 10.12659/MSM.946332
Most Viewed Current Articles
17 Jan 2024 : Review article 6,964,204
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 700,526
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 24,009
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 18,806
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912